ADR-002K
/ Rohto Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 10, 2026
Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG
(clinicaltrials.gov)
- P2 | N=50 | Recruiting | Sponsor: Rohto Pharmaceutical Co., Ltd. | Initiation date: Sep 2025 ➔ Apr 2026 | Not yet recruiting ➔ Recruiting
Enrollment open • Trial initiation date • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure
September 26, 2025
Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG
(clinicaltrials.gov)
- P2 | N=50 | Not yet recruiting | Sponsor: Rohto Pharmaceutical Co., Ltd.
New P2 trial • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure
1 to 2
Of
2
Go to page
1